In Vitro
In vitro log10 reduction antimicrobial efficacy testing was conducted on PrevahexCHX®. A broad spectrum of microorganisms were tested, including gram-positive bacteria, gram-negative bacteria and yeasts as well as several drug-resistant microorganisms. The pathogenic microorganisms included in this study were specifically selected due to their clinical relevance and prevalence as the cause of challenging Healthcare-Associated Infections (HAIs). Antimicrobial efficacy was evaluated at 1-, 3- and 7-day timepoints and PrevahexCHX® consistently achieved a 5.0 log10 or greater reduction at all time points demonstrating ≥10x the antimicrobial performance requirements established by the FDA.
PrevahexCHX® has efficacy of over 5.0 log10 reduction against several multidrug-resistant microorganisms, the pathogens responsible for some of the most difficult-to-treat HAIs facing clinicians today. In contrast, the market leading standard transparent thin film dressing offers no antimicrobial protection to patients.
Versus Drug-Resistant Pathogens
Source: GLP Testing Conducted at Independent Third Party Laboratory, Data on File: entrotech life sciences, llc, Columbus, OH.
Tegaderm is a registered trademark of Solventum Intellectual Properties Company
PrevahexCHX® demonstrates rapid onset of action starting at day 1 and continuing through day 7, thus dramatically outperforming other competitive antimicrobial dressings which can take several days to demonstrate significant efficacy.
* Note: In vitro effectiveness does not predict clinical performance.
1 Holinga GJ, McGuire JE. In vitro antimicrobial effects of chlorhexidine diacetate versus chlorhexidine free base dressings. J Wound Care. 2020; 29(Sup5a): S22-S28.
SurgiClear® is a registered trademark of Covalon Technologies Ltd.
In vitro Antimicrobial Effects of Chlorhexidine Diacetate versus Chlorhexidine Free Base Dressings.
George J. Holinga, PhD, and James E. McGuire, BS
Published in the Journal of Wound Care, Volume 29. Number 5. May 2020.